Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression.
Adaptive Immunity
/ immunology
Adult
Aged
Aged, 80 and over
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
COVID-19
/ epidemiology
Disease Progression
Epidemics
Female
Humans
Immune System Diseases
/ diagnosis
Immunity, Innate
/ immunology
Lymphocyte Subsets
/ immunology
Male
Middle Aged
SARS-CoV-2
/ immunology
Severity of Illness Index
Journal
Life science alliance
ISSN: 2575-1077
Titre abrégé: Life Sci Alliance
Pays: United States
ID NLM: 101728869
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
12
11
2020
revised:
03
12
2020
accepted:
04
12
2020
entrez:
28
12
2020
pubmed:
29
12
2020
medline:
26
1
2021
Statut:
epublish
Résumé
With a rising incidence of COVID-19-associated morbidity and mortality worldwide, it is critical to elucidate the innate and adaptive immune responses that drive disease severity. We performed longitudinal immune profiling of peripheral blood mononuclear cells from 45 patients and healthy donors. We observed a dynamic immune landscape of innate and adaptive immune cells in disease progression and absolute changes of lymphocyte and myeloid cells in severe versus mild cases or healthy controls. Intubation and death were coupled with selected natural killer cell KIR receptor usage and IgM+ B cells and associated with profound CD4 and CD8 T-cell exhaustion. Pseudo-temporal reconstruction of the hierarchy of disease progression revealed dynamic time changes in the global population recapitulating individual patients and the development of an eight-marker classifier of disease severity. Estimating the effect of clinical progression on the immune response and early assessment of disease progression risks may allow implementation of tailored therapies.
Identifiants
pubmed: 33361110
pii: 4/2/e202000955
doi: 10.26508/lsa.202000955
pmc: PMC7768198
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : T32 AI07613-19
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA203702
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007613
Pays : United States
Organisme : NIAID NIH HHS
ID : K08 AI132739
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002384
Pays : United States
Organisme : NIAID NIH HHS
ID : K08 AI139360
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR002385
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2020 Rendeiro et al.
Références
Nat Med. 2020 Sep;26(9):1428-1434
pubmed: 32661393
Infect Control Hosp Epidemiol. 2020 Jun;41(6):750-751
pubmed: 32146921
Nat Commun. 2020 Jul 6;11(1):3434
pubmed: 32632085
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Lancet Rheumatol. 2020 Aug;2(8):e474-e484
pubmed: 32835257
EClinicalMedicine. 2020 Jun 20;24:100418
pubmed: 32766537
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Lancet. 2020 Aug 1;396(10247):320-332
pubmed: 32682491
Ther Clin Risk Manag. 2008 Aug;4(4):767-75
pubmed: 19209259
Nat Immunol. 2009 Jan;10(1):29-37
pubmed: 19043418
BMC Bioinformatics. 2013 Aug 20;14:252
pubmed: 23962281
Nat Commun. 2022 Jan 21;13(1):440
pubmed: 35064122
Viruses. 2019 Sep 04;11(9):
pubmed: 31487968
Semin Immunol. 2018 Feb;35:19-28
pubmed: 29254756
Genome Med. 2021 Jan 13;13(1):7
pubmed: 33441124
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
J Virol. 2004 Jun;78(11):5535-45
pubmed: 15140950
Sci Immunol. 2020 Jul 10;5(49):
pubmed: 32651212
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Immunity. 2020 Sep 15;53(3):685-696.e3
pubmed: 32783921
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Genome Biol. 2018 Feb 6;19(1):15
pubmed: 29409532
Viral Immunol. 2017 Mar;30(2):82-97
pubmed: 28051364
Annu Rev Immunol. 2016 May 20;34:335-68
pubmed: 26907215
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
Nature. 1993 Apr 22;362(6422):758-61
pubmed: 8469287
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
AIDS Res Hum Retroviruses. 1999 Nov 20;15(17):1509-18
pubmed: 10580401
J Allergy Clin Immunol. 1997 Dec;100(6 Pt 2):S97-101
pubmed: 9440553
Nat Biotechnol. 2018 Dec 03;:
pubmed: 30531897
J Clin Invest. 2008 Jan;118(1):294-305
pubmed: 18060041
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
Nature. 2010 May 27;465(7297):492-6
pubmed: 20505730
Cell Death Differ. 2020 Nov;27(11):3196-3207
pubmed: 32514047
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
Front Oncol. 2019 Nov 08;9:1223
pubmed: 31781510
Immunology. 2020 Jul;160(3):261-268
pubmed: 32460357
Br J Haematol. 2020 Oct;191(2):207-211
pubmed: 32679621
Sci Immunol. 2020 Jul 15;5(49):
pubmed: 32669287
Trends Immunol. 2016 Mar;37(3):208-220
pubmed: 26858199
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Cell. 2020 Sep 17;182(6):1419-1440.e23
pubmed: 32810438
Annu Rev Immunol. 2007;25:171-92
pubmed: 17129182
Immunity. 2020 Oct 13;53(4):864-877.e5
pubmed: 32791036
Mayo Clin Proc. 2020 Aug;95(8):1613-1620
pubmed: 32753136
Cell Mol Immunol. 2020 May;17(5):541-543
pubmed: 32203186
Front Immunol. 2020 Jul 03;11:1299
pubmed: 32719675
Medicine (Baltimore). 2017 Jan;96(1):e5275
pubmed: 28072682
Nat Commun. 2020 Jan 29;11(1):577
pubmed: 31996669
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Cell Mol Immunol. 2020 Jun;17(6):650-652
pubmed: 32346099